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Background: Streptococcus agalactiae or Group B Streptococci (GBS) have the ability to access various host sites,
which reflects its adaptability to different environments during the course of infection. This adaptation is due to the
expression of virulence factors that are involved with survival, invasion and bacterial persistence in the host. This
study aimed to characterize GBS isolates from women of reproductive age seen at University Hospital of Londrina,
according to capsular typing, genetic relatedness, antimicrobial susceptibility profile and occurrence of virulence
determinants.
Results: A total of 83 GBS isolates were enrolled in this study. Capsular types Ia (42.2%), II (10.8%), III (14.5%) and V
(30.1%) were identified in most GBS. One isolate each was classified as type IX and non-typeable.
A total of 15 multiple locus variable number of tandem repeat analysis (MLVA) types were identified among the
isolates, seven were singletons and eight were represented by more than four isolates. All isolates were susceptible
to penicillin, ampicillin, cefepime, cefotaxime, chloramphenicol, levofloxacin and vancomycin. Resistance to
erythromycin and clindamycin was observed in 19.3 and 13.3% of isolates, respectively. All isolates resistant to
clindamycin were simultaneously resistant to erythromycin and were distributed in the capsular types III and V. One
isolate showed the constitutive macrolide-lincosamide-streptogramin B (cMLSB) phenotype and ten showed the
inducible MLSB (iMLSB) phenotype. The mechanism of resistance to erythromycin and clindamycin more prevalent
among these isolates was mediated by the gene ermA, alone or in combination with the gene ermB. The isolates
displaying resistance only to erythromycin belonged to capsular type Ia, and showed the M phenotype, which was
mediated by the mefA/E gene. All isolates harbored the gene hylB and at least one pilus variant, PI-1, PI-2a or PI-2b.
Although cylE was observed in all GBS, four isolates were classified as gamma-hemolytic and carotenoid pigment
non-producers.
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Conclusions: Our results indicate the potential virulence of commensal GBS isolates, reinforcing the need for
continued screening for this bacterium to prevent infections. The distribution of capsular and pili antigens, and
MLVA profiles was also identified, which may contribute to the development of new strategies for the prevention
and treatment of GBS infection.
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Virulence traitsBackground
Streptococcus agalactiae (Group B Streptococci – GBS)
can colonize the gastrointestinal and genitourinary tracts
of healthy individuals without any symptoms of disease [1].
Nevertheless, this bacterium can cause life-threatening
invasive diseases in pregnant women, neonates or
non-pregnant adults. Colonized women, during pregnancy
or the postpartum period, are usually asymptomatic, but
GBS may cause bacteremia, urinary tract infections,
chorioamnionitis, endometritis, puerperal sepsis and,
occasionally meningitis and septic thrombophlebitis [2,3].
GBS colonization among pregnant women also increases
the risk of premature delivery and perinatal transmission
of the microorganism to newborns, which can cause fatal
sepsis and meningitis [4,5]. A successful perinatal disease
prevention strategy based on intrapartum chemoprophylaxis
for pregnant women at risk [6] leads to a significant
decrease in GBS infections in neonates [3,6,7]. However, in
the last decades, GBS have been increasingly associated
with invasive disease in non-pregnant adults, mainly in the
elderly, immunocompromised and those with diabetes
mellitus and cancer [3,8,9]. Most importantly, mortality
associated with these patients is frequently higher than for
newborns [3,8]. These data draw attention to the need for
prevention strategies against GBS infections among adults.
Penicillin has been established as a first-line antimicrobial
for the prophylaxis and treatment of GBS infections.
Moreover, clindamycin and erythromycin have been
used as alternatives in penicillin-allergic individuals.
However, resistance to these antimicrobials among
GBS isolated from pregnant and non-pregnant individuals
has been described in several countries [3,9-15], raising
concerns about their use in the treatment of GBS infections.
Resistance to penicillin is frequently associated with
mutation of penicillin-binding proteins (PBP) 2X and
2B [14]. Overall, the mechanisms that confer resistance to
erythromycin include the post-transcriptional methylation
of the adenine residues of 23S ribosomal RNA mediated
by erm genes and efflux of the antibiotic mediated by
a membrane-bound protein encoded by mef genes. The
expression of erm genes results in the MLSB phenotype,
responsible for generating cross-resistance to macrolides,
lincosamides and streptogramin B [16]. On the other
hand, phenotype M, encoded by mef genes, confersresistance only to 14- and 15-membered ring macrolides
(erythromycin and azithromycin) [17].
According to the immunologic reactivity of sialic
acid-rich capsular polysaccharide, GBS are divided into
ten serotypes, Ia, Ib, II-VIII [18] and IX [19]. Different
surveys all over the world have shown the prevalence of
serotypes Ia, Ib, II, III and V as major streptococcal
disease-causing agents [3,7-9,20,21].
The diverse array of clinical manifestations caused by
GBS reflects an efficient adaptability of bacteria to different
host environments. GBS may express virulence factors,
allowing the colonization and invasion of epithelial
barriers, leading to resistance to immune clearance and
persistence in host tissues, which contribute to the
pathogenesis of infection. Besides defining GBS serotypes,
the cell wall-anchored polysaccharide capsule has been
recognized as important virulence factor of this bacterium.
It prevents the deposition of alternative complement
pathway factor C3b on the bacterial surface, resulting
in decreased phagocytosis by macrophages and neutrophils
[22]. In the last decade, a pilus-like structure was identified
in GBS [23] and shown to play an important role in the
adhesion to and invasion of host cells [24], biofilm
formation [25] and resistance to phagocyte killing
[26]. Extracellular β-hemolysin/cytolysin (β-H/C) is a
pore-forming toxin encoded by the chromosomal cylE gene
[27], which is toxic to a broad range of eukaryotic cells,
resulting in cell invasion [28] and evasion of phagocytosis
[29]. The expression of cylE is also associated with the
production of an orange carotenoid pigment that
contributes to the protection of bacteria against the
toxic effects of reactive oxygen species generated by
the oxidative burst mechanism of phagocytic killing
of macrophages [29]. The product of gene hylB, a secreted
hyaluronate lyase, can hydrolyze hyaluronan polymers,
which are components of the extracellular matrix of
human tissues, suggesting that this enzyme can facilitate
the spread of bacteria during infection [30].
In the study described here, GBS isolated from women
at reproductive age with no clinical evidence of strepto-
coccal infection were characterized by phenotypic and
molecular methods. All isolates were tested for capsular
type, hemolysis and carotenoid pigment production. In
addition, the in vitro susceptibility pattern of the isolates
Otaguiri et al. BMC Microbiology 2013, 13:297 Page 3 of 9
http://www.biomedcentral.com/1471-2180/13/297to antimicrobial agents, the genetic relatedness and the
occurrence of virulence determinant genes were also
investigated.
Results
Patients, GBS capsular types and multiple locus variable
number of tandem repeat analysis (MLVA) genotypes
A total of 83 isolates of GBS from women with no clinical
evidence of streptococcal infection were enrolled in
this study. These isolates were taken from the bacterial
collection of the Laboratory of Clinical Microbiology of
University Hospital of Londrina, the major referral center
for healthcare management that serves Londrina city,
besides several localities of Paraná, São Paulo and Mato
Grosso do Sul states, in Brazil. The age of the patients
ranged from 15 to 58 years (median 29.7 years old). GBS
isolates were distributed in five capsular types according
to the multiplex-PCR method, and type Ia (35/83, 42.2%)
was the most frequent, followed by type V (25/83, 30.1%),
type III (12/83, 14.5%) and type II (9/83, 10.8%). One each
of type IX (1.2%) and NT (1.2%) was identified among
isolates. The genetic relatedness of GBS isolates was
assessed by MLVA. By using a cutoff value of 85%
similarity, a total of 15 different MLVA types (MTs)
were identified among the isolates, and overall the diversity
index obtained with this method was 0.84. The largest
groups of similar MLVA profiles consisted of 16
(MT1, 19.3%) and 26 (MT8, 33.7%) isolates. Thirty
five isolates were grouped in six MTs, one with four
(MT2, 4.8%), eight (MT4, 9.6%), and seven (MT7, 8.4%)
isolates each, and three with five (MTs 5, 6 and 13, 6.0%)
isolates each. The other seven (8.4%) had unique MLVA
profiles. Most GBS capsular type Ia were grouped in MT8
(23/35, 65.7%), and the other 12 isolates were distributed
in seven distinct MLVA types. The GBS capsular types V
and III were distributed in seven and three MLVA types
respectively, whereas all isolates displaying the capsular
type II were grouped in MT1, and all the isolates except
one had an identical MLVA profile (Figure 1).
Phenotypic and genotypic characterization of
antimicrobial susceptibility
All isolates were susceptible to penicillin, ampicillin, cefe-
pime, cefotaxime, chloramphenicol, levofloxacin and vanco-
mycin. Resistance to erythromycin and clindamycin was
detected in 16 (19.3%) and 11 (13.3%) isolates, respectively.
All isolates resistant to clindamycin were also resistant to
erythromycin, and among them only one had a constitutive
macrolide-lincosamide-streptogramin B (cMLSB) phenotype
(minimal inhibitory concentration - MIC > 8.0 μg/mL for
both antimicrobials) and harbored the ermB gene. Of the 10
isolates displaying the indutible MLSB (iMLSB) phenotype,
seven carried the ermA gene, whereas one isolate carried
the ermB gene and two both genes. All isolates (n = 5)resistant only to erythromycin showed phenotype M and
carried the mefA/E gene. Resistance to both erythromycin
and clindamycin was detected among isolates belonging
to serotypes V (n = 7) and III (n = 4), which were grouped
in MTs 1, 3, 4, 6 and 7. All isolates resistant only to
erythromycin belonged to serotype Ia and MT8 (Table 1).
Detection of potential virulence traits of commensal GBS
The presence of the nucleotide sequences corresponding
to the cylE, hylB and pilus islands PI-1, PI-2a and PI-2b
was detected by PCR. All isolates harbored the cylE and
hylB genes and at least one pilus island. Four (4.8%) of
the 83 GBS isolates did not produce a hemolytic halo
around the bacterial colonies (Figure 1). Concomitantly,
these isolates were not able to produce the orange
carotenoid pigment in Granada medium. Most of the
isolates harbored PI-2a alone (n = 30, 36.1%) or in
combination with PI-1 (n = 42, 50.6%). PI-2a was distributed
in all capsular types identified in this study, including the
type IX and NT isolates. However, the presence of this pilus
island alone or in combination with PI-1 was found mainly
in capsular type Ia and V, respectively. Besides, PI-1 was
also found in combination with PI-2b (n = 4, 4.8%) and all
isolates belonged to capsular type III. The presence of PI-2b
alone was observed in seven isolates (8.4%) and all
belonged to capsular type Ia. All isolates grouped in
MTs 1 (n = 16, 19.3%), 4 (n = 8, 9.6%), 6 (n = 5, 6.0%)
and 7 (n = 7, 8.4%) harbored PI-1 and PI-2a islands.
In addition, these pili were also detected in isolates
belonged to MTs 2, 3, 5 and 15. All isolates belonging
to MTs 8 (n = 26, 31.6%), 9, 10 and 11 (n = 1, 1.2% each)
and one isolate (1.2%) of MT2 harbored the PI-2a island.
PI-1 and PI-2b was detected only in isolates of MT5
(n = 4, 4.8%), whereas the PI-2b island was detected
in isolates of MTs 12 (n = 1, 1.2%), 13(n = 5, 6.0%)
and 14 (n = 1, 1.2%) (Figure 1). The isolates displaying
the MLSB phenotype harbored the pilus islands PI-1 and
PI-2a, whereas the isolates showing the M phenotype
harbored only the PI-2a.
Discussion
In this study, five capsular types (Ia, II, III, V, IX) were
identified and, except for type IX, all are frequently
associated with GBS infections worldwide [3,7-9,20,21].
The serotypes identified in this study were also detected
in different surveys that were performed with Brazilian
isolates among pregnant and non-pregnant adults. In those
studies, the serotypes Ib [10,11,31] IV [11,12], VI [10] and
VIII [12] were also identified. The genetic diversity of GBS
isolates were assessed by MLVA [32], which is based on
the amplification of polymorphic tandem repeat sequences
(also called VNTR-Variable Number of Tandem Repeats).
It is easy to use, displays shorter time of execution, can be
applied to a small or large numbers of isolates and has
MLVA
SAG2 SAG3 SAG4 SAG7 SAG21 SAG22 Strain Hemolysis Pilus island Capsular MLVA
type genotypes
5.0 4.0 1.0 6.0 0.0 2.0 25 PI-1+ PI-2a II 1
5.0 5.0 3.0 6.0 0.0 2.0 24 PI-1+ PI-2a III 1
6.0 4.0 1.0 6.0 0.0 2.0 39 PI-1+ PI-2a II 1
5.0 4.0 1.0 6.0 0.0 2.0 62 PI-1+ PI-2a II 1
5.0 4.0 3.0 6.0 0.0 2.0 66 PI-1+ PI-2a III 1
5.0 4.0 1.0 6.0 0.0 2.0 71 PI-1+ PI-2a II 1
5.0 4.0 3.0 6.0 0.0 2.0 114 PI-1+ PI-2a III 1
5.0 4.0 1.0 6.0 0.0 2.0 81 PI-1+ PI-2a II 1
5.0 4.0 3.0 6.0 0.0 2.0 113 PI-1+ PI-2a III 1
5.0 4.0 1.0 6.0 0.0 2.0 77 PI-1+ PI-2a II 1
5.0 4.0 1.0 6.0 0.0 2.0 17 PI-1+ PI-2a II 1
5.0 4.0 3.0 6.0 0.0 2.0 107 PI-1+ PI-2a III 1
5.0 4.0 3.0 6.0 0.0 2.0 109 PI-1+ PI-2a III 1
5.0 4.0 3.0 6.0 0.0 2.0 118 PI-1+ PI-2a III 1
5.0 4.0 1.0 6.0 0.0 2.0 48 PI-1+ PI-2a II 1
5.0 4.0 1.0 6.0 0.0 2.0 92 PI-1+ PI-2a II 1
5.0 4.0 3.0 -2.0 0.0 2.0 29 PI-1+ PI-2a V 2
5.0 4.0 3.0 -2.0 0.0 2.0 21 PI-1+ PI-2a Ia 2
5.0 4.0 3.0 -2.0 0.0 2.0 61 PI-1+ PI-2a V 2
5.0 4.0 1.0 0.0 0.0 4.0 94 PI-2a Ia 2
5.0 4.0 3.0 15.0 -2.0 3.0 105 PI-1+ PI-2a V 3
5.0 5.0 3.0 11.0 18.0 3.0 65 PI-1+ PI-2a V 4
5.0 4.0 3.0 11.0 17.0 3.0 70 PI-1+ PI-2a Ia 4
5.0 4.0 3.0 11.0 17.0 3.0 116 PI-1+ PI-2a V 4
5.0 4.0 3.0 11.0 14.0 3.0 47 PI-1+ PI-2a V 4
5.0 4.0 3.0 11.0 15.0 3.0 69 PI-1+ PI-2a V 4
5.0 4.0 3.0 11.0 15.0 3.0 90 PI-1+ PI-2a V 4
5.0 4.0 3.0 11.0 15.0 3.0 93 PI-1+ PI-2a V 4
5.0 3.0 1.0 11.0 15.0 1.0 73 PI-1+ PI-2a V 4
4.0 3.0 2.0 11.0 8.0 3.0 59 PI-1+ PI-2b III 5
4.0 3.0 2.0 11.0 7.0 3.0 104 PI-1+ PI-2b III 5
4.0 3.0 2.0 11.0 8.0 1.0 72 PI-1+ PI-2b III 5
4.0 3.0 2.0 11.0 7.0 3.0 119 PI-1+ PI-2b III 5
5.0 4.0 3.0 11.0 9.0 3.0 111 PI-1+ PI-2a V 5
5.0 4.0 3.0 11.0 23.0 3.0 12 PI-1+ PI-2a V 6
5.0 4.0 3.0 11.0 23.0 3.0 80 PI-1+ PI-2a V 6
5.0 4.0 2.0 11.0 23.0 3.0 112 PI-1+ PI-2a V 6
5.0 4.0 3.0 11.0 23.0 3.0 108 PI-1+ PI-2a V 6
5.0 4.0 3.0 11.0 23.0 3.0 117 PI-1+ PI-2a V 6
5.0 4.0 3.0 11.0 -2.0 3.0 20 PI-1+ PI-2a V 7
5.0 4.0 3.0 11.0 0.0 3.0 13 PI-1+ PI-2a V 7
5.0 4.0 3.0 11.0 -2.0 3.0 64 PI-1+ PI-2a V 7
5.0 4.0 3.0 11.0 -2.0 3.0 68 PI-1+ PI-2a V 7
5.0 4.0 3.0 11.0 -2.0 3.0 115 PI-1+ PI-2a V 7
5.0 4.0 3.0 11.0 -2.0 3.0 84 PI-1+ PI-2a V 7
5.0 4.0 3.0 11.0 -2.0 3.0 1 PI-1+ PI-2a V 7
6.0 4.0 1.0 0.0 11.0 5.0 27 PI-2a Ia 8
5.0 4.0 1.0 0.0 12.0 4.0 23 PI-2a Ia 8
5.0 4.0 1.0 0.0 12.0 4.0 22 PI-2a Ia 8
6.0 4.0 1.0 0.0 11.0 5.0 15 PI-2a Ia 8
5.0 4.0 1.0 0.0 11.0 4.0 31 PI-2a Ia 8
5.0 4.0 1.0 0.0 12.0 4.0 34 PI-2a NT 8
6.0 4.0 1.0 0.0 11.0 5.0 42 PI-2a Ia 8
5.0 4.0 1.0. 1.0 11.0 5.0 43 PI-2a Ia 8
5.0 4.0 1.0 0.0 12.0 4.0 46 PI-2a Ia 8
5.0 4.0 1.0 0.0 11.0 4.0 54 PI-2a Ia 8
5.0 4.0 1.0 0.0 11.0 5.0 56 PI-2a Ia 8
5.0 4.0 1.0 1.0 11.0 3.0 58 PI-2a V 8
5.0 4.0 1.0 0.0 12.0 4.0 50 PI-2a Ia 8
5.0 4.0 1.0 0.0 12.0 4.0 98 PI-2a Ia 8
5.0 4.0 1.0 0.0 12.0 4.0 88 PI-2a Ia 8
6.0 4.0 1.0 0.0 11.0 5.0 2 PI-2a Ia 8
6.0 4.0 1.0 0.0 11.0 3.0 4 PI-2a V 8
5.0 4.0 1.0 0.0 12.0 4.0 6 PI-2a Ia 8
5.0 4.0 1.0 0.0 12.0 4.0 10 PI-2a Ia 8
5.0 4.0 1.0 0.0 12.0 4.0 121 PI-2a Ia 8
5.0 4.0 1.0 0.0 12.0 4.0 120 PI-2a Ia 8
6.0 4.0 1.0 0.0 12.0 4.0 63 PI-2a Ia 8
5.0 3.0 1.0 0.0 11.0 5.0 60 PI-2a Ia 8
5.0 4.0 1.0 0.0 12.0 4.0 49 PI-2a Ia 8
5.0 4.0 1.0 0.0 14.0 4.0 106 PI-2a Ia 8
6.0 4.0 1.0 0.0 9.0 3.0 33 PI-2a Ia 8
6.0 4.0 1.0 0.0 11.0 -2.0 26 PI-2a Ia 9
5.0 4.0 1.0 22.0 9.0 4.0 11 PI-2a IX 10
5.0 4.0 1.0 28.0 12.0 4.0 96 PI-2a Ia 11
5.0 3.0 3.0 27.0 6.0 5.0 55 PI-2b Ia 12
5.0 3.0 4.0 27.0 9.0 4.0 19 PI-2b Ia 13
5.0 3.0 4.0 27.0 9.0 5.0 37 PI-2b Ia 13
5.0 3.0 4.0 27.0 9.0 5.0 89 PI-2b Ia 13
5.0 3.0 4.0 27.0 9.0 5.0 83 PI-2b Ia 13
5.0 3.0 4.0 27.0 9.0 5.0 9 PI-2b Ia 13
5.0 3.0 4.0 0.0 9.0 5.0 35 PI-2b Ia 14
6.0 4.0 3.0 6.0 3.0 -2.0 32 PI-1+ PI-2a III 15
Figure 1 (See legend on next page.)
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Figure 1 Phenotypic and genotypic features of 83 commensal Streptococcus agalactiae isolated from patients seen at University
Hospital of Londrina: distribution of capsular types, pili island, hemolysis pattern and MLVA types. Cluster analysis was performed using
UPGMA algorithm of the Bionumerics v. 4.6 software, with a cutoff value set at 85%. Numbers of repeats are showed in each MLVA marker. The
number −2.0 was assigned if no PCR product could be amplified. Hemolysis in agar plate containing 5% sheep blood.
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bacteria species. In addition, it has higher discriminatory
power than Multi Locus Sequencing Typing (MLST), the
reference method for genotyping Streptococcus spp.
[32,33]. The diversity index obtained with MLVA for this
bacterial population was 0.84, lower than observed by
others [32,33]. However, despite the close relatedness of
several isolates, as judged by the capsular type and pres-
ence of pili islands, this genotyping scheme discriminated
the GBSs in this study. In fact, a total of 15 different
genetic groups were identified among these isolates.
SAG7, SAG21 and SAG22 presented higher degree of the
variation in the number of repeats among the isolates,
corroborating the data of Haguenoer et al. [32]. Although
no statistical correlation was performed, it was observed
that isolates belonging to the capsular type II were
confined to MT1, indicating that the genetic background
of this serotype may be well conserved. Higher number of
isolates may corroborate these findings.Table 1 Macrolide/lincosamide resistant Streptococcus agalact
antimicrobials resistance features
Isolate Source MLVA Genotypesa Capsular typeb Erythromycin resi
15 Urine 8 Ia
22 Urine 8 Ia
46 Urine 8 Ia
120 Urine 8 Ia
121 Swab 8 Ia
66 Urine 1 III iM
109 Urine 1 III iM
113 Urine 1 III iM
114 Urine 1 III iM
65 Urine 4 V iM
105 Urine 3 V iM
108 Urine 6 V iM
112 Urine 6 V iM
115 Swab 7 V cM
116 Swab 4 V iM
117 Urine 6 V iM
aThe genetic diversity was assessed by MLVA typing [32]. A cutoff value of 85% sim
by multiplex-PCR [43]. cErythromycin resistance phenotype was determined by the
determined by PCR. (+) Presence; (−) Absence. eThe minimum inhibitory concentrat
Erythromycin (E).All isolates were susceptible to the antimicrobials evalu-
ated in this study, except erythromycin and clindamycin.
Although it was not an epidemiological investigation, the
overall rate of erythromycin resistance among the isolates
analyzed was 19.3%. Previous epidemiological and bacterial
collection data from Brazilian GBS isolates showed that
erythromycin resistance ranged from 4 to 14% [10-13]. A
higher incidence rate was observed in other regions, where
erythromycin resistance up to 40% among GBS isolates
was detected in Europe [15] and USA [3,9]. In this study,
resistance to both erythromycin and clindamycin was
observed in GBS isolates of capsular types III and V, whereas
the isolates displaying resistance only to erythromycin
were exclusively found in the Ia capsular type. Similar
results were previously obtained by other authors [3,10];
however, resistant isolates for both antimicrobials were
also observed among the Ib, II, IV, VI and VIII capsular
serotypes [3,34]. The mechanisms of macrolide resist-
ance are mediated by ermA, ermB and mefA/E, andiae: distribution of capsular type, MLVA genotypes and
stance phenotypec Erythromycin resistance genes
d MIC (μg/mL)e
ermA ermB mefA/E DA E
M - - + 0.06 4.0
M - - + 0.06 4.0
M - - + 0.06 4.0
M - - + 0.06 4.0
M - - + 0.03 2.0
LSB - + - 0.06 2.0
LSB + - - 0.03 2.0
LSB + + - 0.03 2.0
LSB + - - 0.06 > 8.0
LSB + - - 0.06 4.0
LSB + - - 0.06 8.0
LSB + - - 0.06 8.0
LSB + - - 0.06 4.0
LSB - + - > 8.0 > 8.0
LSB + + - 0.06 8.0
LSB + - - 0.06 4.0
ilarity was applied to define MLVA types. bThe capsular type was identified
double-disk diffusion method [46]. dThe presence of specified gene was
ions (MIC) were determined by the agar-dilution method. Clindamycin (DA);
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study were in accordance with the macrolide-resistance
phenotypes. These results were also observed by others
[10-13]. The increasing numbers of isolates showing
macrolide resistance together with the description of re-
duced susceptibility to penicillin emphasize the need for
continued monitoring of antimicrobial susceptibility
profile to identify the emergence of resistance among
GBS isolates.
Data of the potential virulence of GBS isolates from
Brazil are limited. Three genomic islands encoding the
structurally distinct types of pili (PI-1, PI-2a and PI-2b)
were identified in GBS. These pili are organized in two
different loci, where PI-2a and PI-2b are located at the
same chromosomal locus, with these being mutually
exclusive [35]. To our knowledge, this is the first study
describing the prevalence of the pilus island in Brazilian
GBS isolates, and at least one pilus type was detected
among the isolates, supporting their use as an antigen
for vaccine development. The combination of PI-1 and
PI-2a was the most prevalent among the GBS isolates,
and this result is in agreement with previous reports
[21,36]. In addition, the presence of this combination
was correlated with maternal colonization and invasive
disease in adults [36].
The cyl locus of GBS consists of a cluster of twelve
genes [27], and some of them can modulate cylE expression
and secretion [37], which is crucial for β-H/C activity. This
toxin can promote the invasion of epithelial or endothelial
cells [28], facilitate their persistence and intracellular
survival [29], and enable their dissemination at host sites.
Besides, acting as a virulence factor, CylE is associated with
the characteristic translucent halo around GBS colonies
grown on blood agar plates and production of orange
carotenoid pigment on specific chromogenic agar, features
that are used for presumptive identification of S. agalactiae.
In this study, four GBS isolates were non-hemolytic
and simultaneously non-pigment producers. Indeed,
approximately 3% of GBS isolates are non-hemolytic
[38], emphasizing the need to develop new methods that
combine identification and detection of antimicrobial
resistance for these bacteria.
The role of hyaluronidase in the pathogenesis of GBS
infections is still unclear, but it is postulated that this
enzyme can facilitate the invasion and dissemination of
GBS during infection. The expression of this enzyme has
been associated with GBS isolated from invasive infections
[39]; however, hyaluronidase activity has also been
detected in commensal GBS isolates from women’s
genital tract [40].
Conclusions
In conclusion, we identified the predominant occurrence
of capsular types Ia, II, III and V among commensal GBSsisolated from women at reproductive age seen at University
Hospital of Londrina, Paraná. The GBS isolates harbored
at least one pilus island. Our findings are in agreement
with a higher proportion of capsular types and distribution
of pili previously reported among GBS isolated from
different countries. These data support the notion of
developing of a vaccine globally effective against this
opportunistic bacterium. We also detected resistance
to erythromycin and clindamycin and the occurrence
of the genes encoding virulence determinants cylE
and hylB among these isolates, reinforcing the need for con-
tinued monitoring of GBS to prevent the development of
infections. In addition, a total of 15 different genetic groups
were identified, and isolates belonging to the capsular
type II were confined to MT1. Besides, resistance only to
erythromycin was observed in GBS isolates belonging
to capsular type Ia and MT8, whereas isolates resistant to
both erythromycin and clindamycin were distributed over
various capsular and MLVA types. Higher number of isolates
may corroborate these findings.
Methods
Microorganisms
A total of 83 non-duplicate colonizing GBS isolates
recovered from vaginal-rectal swabs (n = 31) and urine
(n = 52) of women seen at University Hospital of
Londrina, Paraná, Brazil from March to September of
2012 were randomly taken from the bacterial collection of
the Laboratory of Clinical Microbiology of Universidade
Estadual de Londrina. The isolates were classified according
to CDC definitions of healthcare-associated infections [41].
Cultures were performed from the patients as part of the
hospital surveillance study for healthcare-associated
infections agents. All streptococci were identified to the
species level by standard phenotypic methods on the basis
of colony morphology, Gram staining, catalase and CAMP
(Christie, Atkins, Munch-Petersen) tests, after growth on
Muller-Hinton agar (MHA) containing 5% sheep blood at
37°C for 24 h. Concomitantly, tests for growth in 6.5%
NaCl and in Granada™ Biphasic broth (Biomérieux),
bile-esculin or sodium hippurate hydrolysis, and suscepti-
bility to bacitracin and sulfamethoxazole plus trimethoprim
were also performed. Bacteria were kept at -20°C in Tryptic
Soy Broth (TSB, Oxoid) containing 20% glycerol and 5%
sheep blood.
DNA extraction
Total DNA of all GBS isolates was extracted following
the procedures described by de-Paris et al. [42] with
minor modifications. Briefly, a single bacterial colony
was added to 3 mL TSB and incubated at 37°C for 24 h.
The cultures were centrifuged at 10,000 x g for 5 min,
the bacterial pellets were washed twice with sterile 0.15
M phosphate-buffered saline (PBS), pH 7.2, resuspended
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mM EDTA and boiled (100°C) for 20 min. Cellular
debris was removed by centrifugation, and a 2-μL aliquot
of supernatant was used in all amplification reactions.
Capsular typing and genotyping
The identification of capsular type (Ia, Ib, II-IX) of all
GBS isolates was performed by multiplex PCR assay as
described by Imperi et al. [43]. Non-typeable isolates
were designated as NT.
The genetic clonal relatedness of the isolates was
analyzed by MLVA using six markers named as SAG2,
SAG3, SAG4, SAG7, SAG21 and SAG22 as described by
Haguenoer et al. [32]. Cluster analysis were performed
using the UPGMA algorithm of the Bionumerics v. 4.6
software (Applied Mathematics, Kortrijk, Belgium), and a
cutoff value of 85% similarity was applied to define MLVA
types. The genetic diversity in MLVA profiles of the isolates
was calculated with Hunter-Gaston index [44].
Antimicrobial susceptibility pattern
GBS isolates were tested for antimicrobial susceptibility
to nine antimicrobials (ampicillin, cefepime, cefotaxime,
chloramphenicol, clindamycin, erythromycin, levofloxacin,
penicillin and vancomycin) using the disk-diffusion method.
The minimum inhibitory concentrations (MIC) for erythro-
mycin and clindamycin were determined by the agar-dilution
method. MIC was determined at 100% growth inhibition.
Both methods were performed and interpreted according toTable 2 Description of primers used in PCR for the detection of
genes

























ahylB, hyaluronate lyase; cylE, hemolysin/cytolysin (β-H/C); PI-1, PI-2a, PI-2b, pilus isla
B; mefA/E resistance only to 14- and 15-membered ring macrolides. bThe nucleotide
databases used for specific primer design.the Clinical Laboratory Standards Institute [45]. The GBS
phenotypes showing resistance to erythromycin and
clindamycin were determined by the double-disk diffusion
method as described by Seppala et al. [46]. Streptococcus
pneumoniae ATCC 49619 and Enterococcus faecalis ATCC
29212 were used as controls.
PCR primer design and detection of virulence
determinants and erythromycin and clindamycin
resistance encoding genes
The nucleotide sequences of virulence determinants
(cylE, hylB and pilus islands encoding PI-1, PI-2a and
PI-2b) and erythromycin and clindamycin resistance
(ermA, ermB and mefA/E) encoding genes from S. agalactiae
deposited in the GenBank/EMBL databases were analyzed
using the BioEdit v.7.2.0 software. The sequences were
aligned using ClustalW and a consensus sequence for each
gene was used for specific primer design (Table 2). PCR was
performed in a final volume of 25 μL containing 20 mM
Tris–HCl, pH 8.4, 5 mM KCl, 1.5 mM MgCl2, 100 μM of
each dNTP, 5 pmol of each forward and reverse primer,
2.5 U Taq DNA polymerase (Invitrogen, São Paulo, Brazil),
and 2 μL of genomic DNA. The amplification reactions
were performed in a Veriti® 96-well Thermal Cycler
(Applied Biosystems) with an initial denaturation at
95°C for 1 min, followed by 35 cycles of 95°C for 30 s,
annealing at 60°C for 1 min and an extension step at 72°C
for 45 s. Negative control reactions without any template
DNA were carried out simultaneously. The identity of thevirulence markers and erythromycin/clindamycin-resistance









nds; ermA, ermB cross-resistance to macrolides-lincosamide-streptogramin
sequences of Streptococcus agalactiae genes deposited in the GenBank/EMBL
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nucleotide sequences with a 3730xl DNA Analyzer
(Applied Biosystems) using the Big Dye® Terminator
v.3.1 Cycle Sequencing Kit. Search for homologies in
the GenBank/EMBL databases was carried out with
the Blast algorithm.
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